Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment
研究单位：[1]Shanghai Junshi Bioscience Co., Ltd.[2]The Fifth Medical Center of PLA General Hospital[3]Beijing Hospital[4]Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
研究目的：
This multicenter, randomized, double-blind study will evaluate the efficacy and safety of Toripalimab (JS001) combined with nab-paclitaxel compared with placebo combined with nab-paclitaxel for first/second line treatment of metastatic or recurrent triple-negative breast cancer (TNBC).
